Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.
- LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.
- The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries.
- There was no difference in the proportion of patients with treatment-related Adverse Events (AEs) between the alvelestat and placebo arms.
- The data from the ATALANTa study are expected to further support the ongoing partnering process for the alvelestat Phase 3 program.